Navigation Links
Mesothelioma Law Firm Baron & Budd Calls Attention to Veterans Suffering from Asbestos-Related Diseases
Date:11/11/2013

g the health of our heroes at risk. When our mesothelioma lawyers represent someone who suffered asbestos exposure during military service, we take action against the manufacturers who knowingly hid the dangers of asbestos from the U.S. Army, Navy, Air Force and Marines.

Sadly, the U.S. Navy has been the most affected branch of the Armed Forces, and Baron & Budd has represented numerous Naval veterans, including the family of Admiral Elmo Zumwalt, Jr., who served as Chief of Naval Operations during the 1970s.

The U.S. Army used asbestos when constructing installations that housed soldiers. The toxin has been found in nearly every portion of these installations, from the roof to the flooring to the plumbing system. Even though asbestos use was discontinued in the military in the 1970s, asbestos has been found in many older installations as recently as the 1990s, according to articles on the Mesothelioma News website published in 2012. (http://www.mesotheliomanews.com/asbestos/veterans-mesothelioma-asbestos/)

If you or someone you know is a veteran who has been diagnosed with this devastating disease, call one of our mesothelioma attorneys at 1.866.855.1229 or visit our website http://www.baronandbudd.com/areas-of-practice/mesothelioma-attorney to learn how we may be of assistance.

About Baron & Budd, P.C.

The national mesothelioma law firm of Baron & Budd, P.C. has a more than 30-year history of “Protecting What’s Right” for asbestos sufferers and their families. As one of the first law firms to successfully litigate an asbestos lawsuit, Baron & Budd continues to actively represent veterans, industry workers and others who are suffering as a result of exp
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Setbacks in Mesothelioma Research Possible Due to Closure of the Only Federally-Funded Mesothelioma Program
2. CME Course to Feature International Experts on Mesothelioma
3. Overlooked lymph nodes in rib cage have prognostic power for mesothelioma patients
4. Congressional Briefing on Mesothelioma Educates Staffers
5. Mesothelioma Awareness Day Sheds Light on Deadly Cancer
6. MRHFM Raises Donations and Awareness for Mesothelioma Awareness Day September 26
7. Shrader Law Offering New Services for Mesothelioma Diagnosis Resolutions
8. New York Area Mesothelioma Specialists Present to Patients at Special Event
9. Foundation Mobilizes Volunteers to Raise Awareness of Mesothelioma
10. Mesothelioma Resource Site Mesothlioma Hope Offers New Information Package to Victims and Families
11. Shrader Law Announces New Resources for Shipyard Mesothelioma Claims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... University of California, San Diego School of Medicine report ... suffered a recent major loss are more likely to ... The study is published in this month,s issue of ... Because compassionate behaviors are associated with better health and ... into ways to improve the outcomes of individuals whose ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... cause of neuronal death in Parkinson,s disease is still ... be mistaken for foreign invaders and killed by the ... diseases like type I diabetes, celiac disease, and multiple ... April 16, 2014, in Nature Communications . , ... Parkinson,s disease; but if true, it could lead to ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... Components Corporation (ICC), an established global leader in ... a new series of high-efficiency AC-DC external power ... devices. Marketed under the Elpac Power Systems brand, ... company,s rapidly expanding portfolio of high-efficiency, high-reliability power ...
... Now Have Access to Low-Price Generic Options, Helping Consumers ... Stores Inc. (WMT) today announced its list of up ... will now be accessible to physicians using an Epocrates ... device. Physicians will now be better equipped to ...
... in Light of Economic Downturn, According to New ... HealthLeaders-InterStudy, a leading provider of managed care ... efforts in Louisiana and Rhode Island will likely ... downturn, particularly as Medicaid populations grow.According to the ...
... MOUNTAIN VIEW, Calif., Feb. 19 Based on its ... Frost & Sullivan recognizes Horphag Research Ltd. with the ... of the Year Award. The award acknowledges the company,s ... 40 years, aimed at validating the health benefits of ...
... Inc. (Nasdaq: CADX ) announced today that it ... shares of the Company,s common stock at a price of ... approximately 6 million additional shares of the Company,s common stock, ... of $7.84 per share, for aggregate gross proceeds of approximately ...
... - Defyrus Inc. today announced the signing an ... by the United Kingdom,s Defence Science and Technology ... Dstl,s commercialization company. These patents form the intellectual ... programs. Defyrus and Ploughshare Innovation Ltd plan to ...
Cached Medicine News:Health News:Elpac Power System 150-Watt Commercial External Power Supply Features Industry-Leading Efficiency and Power Density 2Health News:Wal-Mart's $4 Generic Prescription Drug List Added to Epocrates' Drug Reference Application 2Health News:Wal-Mart's $4 Generic Prescription Drug List Added to Epocrates' Drug Reference Application 3Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 2Health News:Medicaid Reform Efforts Underway in Louisiana and Rhode Island 3Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 2Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 3Health News:Frost & Sullivan Recognizes Horphag's Pioneering R&D Efforts in Health Ingredients 4Health News:Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock 2Health News:Cadence Pharmaceuticals Completes $86.6 Million Private Placement of Common Stock 3Health News:Vaccine patent portfolio licensed from UK Ministry of Defence 2
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Shire plc (LSE: SHP, Nasdaq: ... a study showing that coadministration of the ADHD medication VYVANSE(R) ... OTC(R) 40 mg (20 mg X 2), did not alter ... d -amphetamine to be reached in the subjects evaluated. ...
... trials begin enrollment in May 2009; Reinforces Lilly,s commitment ... 21 Eli Lilly and Company (NYSE: ... this month in two separate but identical Phase III ... an anti-amyloid beta monoclonal antibody being investigated as a ...
Cached Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 2Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 3Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 4Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: